Partnership / Collaboration · GCC · Announced 9 Nov 2026

M42 → ADCAN Pharma

ADCAN Pharma and M42 signed an MoU at Abu Dhabi Future Health Summit 2026 to explore CDMO work through Glenmark, UAE registration of an ADC oncology product, and clinical-trial support for M42's CRO, IROS.

Parties: M42 (United Arab Emirates) → ADCAN Pharma (United Arab Emirates)

Value
Undisclosed
Territory
United Arab Emirates, with export markets
Therapeutic area
Oncology
Assets
ADC oncology product (not named); CDMO secondary packaging services
Announced
9 Nov 2026

Our analysis

Why this matters

ADCAN Pharma, a UAE-based manufacturer, and M42, the Abu Dhabi health group built on AI, technology and genomics, signed a memorandum of understanding at Abu Dhabi Future Health Summit 2026 to explore collaboration in pharmaceutical manufacturing and clinical research. The announcement was published on 9 November 2026. It was signed by ADCAN CEO Dr. Fokion Sinis and Dr. David Kavanagh, Acting COO of M42's Integrated Health Solutions.

The MoU links three things: a contract manufacturing opportunity through Glenmark Pharmaceuticals, registration of an advanced antibody-drug conjugate (ADC) for cancer in the UAE, and support for clinical trials run by IROS, M42's contract research organization. Glenmark has already completed a quality audit of ADCAN's facility.

The full analysis is free to read with a work email on this page.

Source: Mid-East.Info

More deals involving M42 or ADCAN Pharma

Latest deals

All GCC deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →